Yazar "Yilmaz, E" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Basic nutrients and element contents of white cheese of diyarbakir in turkey
    (Elsevier Sci Ltd, 2004) Merdivan, M; Yilmaz, E; Hamamci, C; Aygun, RS
    Basic nutrients, moisture, fat and protein, and concentrations of 15 major and trace elements in total and fatty parts of Diyarbakir white cheese were evaluated for compositional differences. Elements were determined using inductively coupled plasma atomic emission spectrometry, while fat was determined by supercritical extraction and protein by protein/nitrogen analyzer. Diyarbakir brine and melt cheeses have lower humidity and higher protein than market brine cheese samples. The fat level was 14-18% for all cheeses. The levels of investigated major and trace elements were much higher in three types of cheese samples. Except for Zn and Mn, the other investigated elements were found in fairly low concentrations and at variable ranges in the fatty part of cheese samples. The elements, Mg among major elements and Fe among trace elements, were highest in that part. Na and Ca as major and Zn, Fe and Al as trace elements were found at maximum levels, especially in Diyarbakir melt cheese. Also, levels correlations between basic nutrients, basic nutrients and elements and element pairs were investigated. (C) 2003 Published by Elsevier Ltd.
  • [ X ]
    Öğe
    Behcet's disease and renal failure
    (Oxford Univ Press, 2003) Akpolat, T; Diri, B; Oguz, Y; Yilmaz, E; Yavuz, M; Dilek, M
    Background. The aims of this study were (i) to investigate the prevalence of Behcet's disease (BD) among dialysis patients in Turkey, (ii) to report the clinical characteristics of patients with BD and endstage renal disease (ESRD), (iii) to evaluate the effect of ESRD on course and activity of BD and (iv) to analyse the published data about BD and renal failure. Methods. A questionnaire investigating BD among dialysis patients was submitted to 350 dialysis centres and we obtained the data for 20 596 patients from 331 dialysis centres. We submitted a second questionnaire regarding clinical characteristics of the patients with BD and ESRD. The PubMed and Web of Science databases were used for the analysis of BD and renal failure. Results. Fourteen patients with BD were determined and the prevalence of BD was 0.07% among 20 596 dialysis patients in Turkey. None of the patients has had a new manifestation of BD after initiation of haemodialysis treatment. The analysis of previous data about renal BD demonstrated 67 patients with renal failure. Conclusions. The most common cause of renal failure in BD is amyloidosis. Routine urine analysis and measurement of serum creatinine and blood urea nitrogen levels are needed for early diagnosis. Vascular access-related problems are common and the activity of BD appears to decrease in patients with ESRD after initiation of haemodialysis.
  • [ X ]
    Öğe
    The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin
    (Georg Thieme Verlag Kg, 2004) Tuzcu, A; Bahceci, M; Yilmaz, E; Bahceci, S; Tuzcu, S
    Background: Patients with end-stage renal disease (ESRD) are known to have insulin resistance. Treatment with EPO is associated with improvement in insulin sensitivity in uremic patients. The aim of this study was to compare insulin sensitivity and pancreatic B cell function in adult non-diabetic uremic hemodialysis patients treated with or without rHuEPO. Subjects and Methods: Three groups of subjects were included to the study: hemodialysis patients treated with rHuEPO [EPO(+) group] or without rHuEPO [EPO(-) group], and healthy controls. Anthropometrical parameters, lipid levels, fasting glucose and insulin levels were measured in all subjects. Homeostasis Model Assessment (HOMA) was used to compare insulin sensitivity. ANOVA, independent t-test, and Pearson correlation were used for statistical analysis. Results: Mean insulin level of control group (20.04 +/- 7.2 pmol/l) was significantly lower than EPO(+) group (p<0.04) and EPO(-) group (p<0.0001). HOMA-(%B) levels in the EPO(+) group were significantly lower than in the EPO(-) group (106 +/- 42, 140 +/- 63 respectively, p<0.02). HOMA(%B) levels in the control group (66 17) were significantly lower than in the EPO(+) and EPO(-) group (p<0.005 an p<0. respectively). HOMA-(%S) levels in the EPO(+) groups was significantly higher than in the EPO(-) group (91 +/- 40, 56 +/- 26, respectively; p<0.01). HOMA-(%S) levels of control group (125 +/- 24) was significantly higher than EPO(+) and EPO(-) groups (p<0.02, p<0.0001 respectively). We found a positive correlation between duration of erythropoietin treatment and insulin sensitivity (r = 0.484, p<0.002). Conclusions: Firstly, patients treated with EPO are insulin sensitive compared to patients not treated with EPO. Secondly, duration of erythropoietin treatment is positively correlated with insulin sensitivity in hemodialysis patients.